RetinalGenix Technologies Inc.

RetinalGenix Technologies Inc. is a U.S.-based medical technology company organized around the development of ophthalmic products and procedures for retinal disease. The company is structured as a development-stage enterprise focused on bringing retinal diagnostics and treatment-related technologies to market.

0.01

0.01

— RetinalGenix Technologies Inc.
%
Retinal diagnostics40% Technologies intended to detect, evaluate, or monitor retinal disease.
Ophthalmic treatment devices35% Devices and tools used in retinal or eye-care procedures.
Product development services15% Internal development work to advance ophthalmic technologies toward market.
Regulatory and commercialization support10% Activities related to product approval, launch preparation, and market entry.

The company’s end customers are expected to be eye-care professionals, ophthalmology practices, and medical...

  • Ophthalmology practicesprimary

    Buy retinal diagnostics or treatment tools to support clinical eye-care workflows.

  • Hospitals and surgical centersprimary

    Use ophthalmic devices in procedural settings for retinal care.

  • Distributors and channel partnerssecondary

    Help commercialize and place products into eye-care markets.

  • Clinical and research institutionsemerging

    Evaluate new retinal technologies for validation and adoption.

RetinalGenix Technologies Inc. is headquartered in the United States and appears to operate primarily from a U.S...

  • •Headquartered in the United States
  • •No country revenue breakdown disclosed in the available excerpts
  • •Commercial exposure likely tied to U.S. ophthalmology markets
  • •Future expansion would depend on regulatory approvals in target markets

The company’s strategic focus is to complete product development and move retinal technologies toward regulatory...

01
Product development completionshort-term

The company must finish development before it can generate commercial demand.

02
Regulatory approvalshort-term

Medical devices require clearance or approval before broad commercialization.

03
Commercialization build-outmedium-term

Adoption by clinicians and institutions determines whether the platform can scale.

The company is exposed to development-stage execution risk, including the possibility that products do not reach...

critical

Going concern and financing risk

Development-stage companies need external capital to fund operations and product development.

Scope
Liquidity and continuity of operations
Materiality
high
high

No commercial revenue

The company has not yet generated sales, so value depends on future product launch success.

Scope
Entire business model
Materiality
high
high

Regulatory approval risk

Ophthalmic devices typically require regulatory clearance before commercialization.

Scope
Product launch timeline
Materiality
high
high

Internal control weakness

Management disclosed ineffective internal controls and a material weakness from lack of segregation of duties.

Scope
Financial reporting reliability
Materiality
high
medium

Clinical adoption and reimbursement risk

Even approved medical products may face slow uptake if benefits are not compelling or reimbursement is limited.

Scope
Commercialization success
Materiality
medium
Going concern assessment
Affects disclosure, valuation, and solvency analysis
Internal control over financial reporting
Raises risk of misstatement and audit scrutiny
Equity financing and share issuance
Can dilute shareholders and affect per-share metrics
Development-stage expense recognition
Suppresses near-term earnings until commercialization

OCULAR THERAPEUTIX, INC

OCUL · Pharmaceutical Preparations

Regenerative Medical Technology Group Inc.

RMTG · Retail-Retail Stores, NEC

Opus Genetics, Inc.

IRD · Pharmaceutical Preparations

SOLIGENIX, INC.

SNGX · Pharmaceutical Preparations

REGENXBIO Inc.

RGNX · Biological Products, (No Diagnostic Substances)

4D Molecular Therapeutics, Inc.

FDMT · Biological Products, (No Diagnostic Substances)

: 29.4.2026